✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Status◇ research
Acquired
Exit Type◇ research
Acquisition
Subsequent Funding◇ research
$3,650,000
Received VC Funding◇ research
—
Current Employees◇ research
—
Peak Employees◇ research
18
Patents◇ research
5 filed
SBIR/STTR Awards◇ research
$225,000
Filed Form D◇ research
No
Used Crowdfunding◇ research
No
Notes
KY Angel PDF shows $870,000 actual KAITC investment across completed 2015 and 2017 entries, with one 2018 row marked inactive. HHS TAGGS shows an NIH SBIR award of $225,000 tied to Hera Testing Laboratories in 2015. Kentucky's business prospectus still listed Hera Testing Laboratories dba Hera BioLabs in 2024, but Demeetra announced in January 2026 that it had completed the acquisition of Hera BioLabs, securing expanded rights to the Super piggyBac platform. This supports coding the company as acquired.
[Deep research 2026-04-11] CB Insights data shows total funding of $3.65M with most recent round of $1.07M circa 2022. Company filed 5 patents with focus on biotechnology, transcription factors, and clusters of differentiation. Key technology included SRG™ platform (double knockout Sprague-Dawley rat for immunodeficiency research). Headquarters confirmed at 2277 Thunderstick Drive, Suite 500, Lexington, KY. Post-acquisition, herabiolabs.com redirects to Demeetra acquisition notice. No crowdfunding campaigns or SEC Form D filings found. Sources: CB Insights company profile, Demeetra acquisition announcement.
Last updated: Apr 11, 2026 · Evidence score: 5/5